Figure 1.
Rituximab activates B cell receptor signaling as inferred by CCL4 and CCL3 expression
(A–D) CCL4 (A + B) and CCL3 (C + D) expression was assessed in SU-DHL4 cells by qRT-PCR after 150-min treatment with rituximab (R), rituximab F(ab‘)2 fragments (R F(ab‘)2), or with trastuzumab (Tra) relative to untreated control samples (Ctrl). Where applicable (B + D), cells were treated with the SYK inhibitor R406 or with DMSO vehicle control (Ctrl) for 48 h. Statistical significance was tested by unpaired parametric t tests based on 3 biological replicates for each treatment condition. Mean with range is plotted. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001, ∗∗∗∗p<0.0001, ns = not significant, as calculated by unpaired non-parametric t tests.